Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 3

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
153,871)Research and development  (12,139)  (11,475)General and administrative (including $1,044 and $nil of rental expenses to related party for the periods ended March 31, 2025 and 2024, respectively)  (391,876)  (315,794)Fair value loss on investments in equity securities  (68,497)  (44,297)Provision for expected credit losses  (40,124)  (120,469)TOTAL OPERATING EXPENSES  (1,053,331)  (645,906)         LOSS FROM OPERATIONS  (618,418)  (79,028)         FINANCE COSTS  (4,909)  (4,661)         LOSS BEFORE TAX  (623,327)  (83,689)         Tax expense  -   (20,068)         NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $(623,327) $(103,757)         Other comprehensive income/(loss)        Foreign currency translation gain/(loss)  72,159   (209,908)         COMPREHENSIVE LOSS $(551,168) $(313,665)         Earnings per share - Basic and diluted  (0.035)  (0.006)Weighted average number of common stocks outstanding, Basic and Diluted #  17,967,663   17,667,663 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 12.

See accompanying notes to the condensed consolidated financial statements.

 6Table of Contents

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

AS OF MARCH 31, 2025 AND 2024 

(Amount expressed in United States Dollars (“US$)) 

(Unaudited)

  Common stock   Additional      Accumulated other   Total   Number of shares  Amount   paid in capital  Accumulated deficit  comprehensive  loss